Sulfonylureas in the Treatment of Type 2 Diabetes Mellitus: A Fresh Look and New Insights
- PDF / 210,939 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 33 Downloads / 170 Views
EDITORIAL
Sulfonylureas in the Treatment of Type 2 Diabetes Mellitus: A Fresh Look and New Insights Aus Alzaid
Received: January 29, 2020 Ó The Author(s) 2020
Keywords: Cardiovascular outcomes; Guidelines; Sulfonylureas; Type 2 diabetes mellitus Key Summary Points In this editorial, the issues raised in each of the articles included in this supplement issue of Diabetes Therapy are introduced, including their focus on reappraisal of sulfonylureas (SUs) in the treatment of type 2 diabetes mellitus (T2DM). SUs have been available for over 50 years, with the latest generation of SUs associated with effective antihyperglycaemic efficacy but a lower risk of adverse effects relative to earlier generations of SUs. The wide clinical benefits of SU treatment in T2DM are reviewed in this supplement, as well as how international and national guidelines recommend their use in patients with T2DM.
Enhanced Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare. 12030267. A. Alzaid (&) Diabetes Consultant, PO Box 300064, Riyadh 11372, Saudi Arabia e-mail: [email protected]
In recent years, remarkable changes have taken place in the treatment of type 2 diabetes mellitus (T2DM). The introduction of many new and exciting medications and drug classes have enriched and expanded the choice of therapies available to treat this increasingly prevalent and burdensome disease. In addition, the general approach to disease management has evolved from a strictly physician-driven treatment approach to an all-inclusive patientcentred care [1]. In the midst of the current change and adjustment however, it is incumbent upon us to reappraise the role of established medications, such as the sulfonylureas (SUs), in order to define their rightful place in this dynamic treatment landscape of T2DM therapies. Since their first introduction into clinical practice over 50 years ago, SUs have incredibly maintained a consistent and strong presence as valuable agents in the treatment of T2DM [2]. The class itself has undergone structural and ‘‘generational’’ changes over the years, yielding modified medications that offer maximised efficacy with minimised risks of adverse effects [2]. SUs, especially later-generation ones, effectively lower blood glucose levels and have welldefined adverse events and cardiovascular safety profiles relative to other therapies [3–7].
Diabetes Ther
A recent symposium, entitled ‘‘SUs in the treatment of T2DM: a fresh look and new insights’’ held on Wednesday September 18, 2019 during the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, presented recent data for SUs, with the aim of going beyond the low cost and affordability of SUs to determine the main scientific evidence and wider clinical benefits behind the popular use of SUs in the treatment of T2DM. This supplement of Diabetes Therapy provides summaries of the three presentations made during the symposium by three international experts in the field. In the first o
Data Loading...
